multiple myeloma

Individualized therapy in Multiple Myeloma

Presented by: Shaji Kumar, M.D., Mark and Judy. Mullins Professor of Hematological Malignancies. Chair, Myeloma and Amyloidosis Group, Mayo Clinic,…

1 year ago

FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval…

1 year ago

FDA Approves Talquetamab-Tgvs For Adults with Relapsed Or Refractory Multiple Myeloma Patients with at least Four Prior Lines of Therapy

By Dr. Anish Shah Bronx Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs…

1 year ago

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which…

2 years ago

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by…

2 years ago